Novartis AG (NVS)
| Market Cap | 262.71B +5.8% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.61 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 20.59 |
| Forward PE | 14.87 |
| Dividend | $3.08 (2.23%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 875,013 |
| Open | 138.14 |
| Previous Close | 137.70 |
| Day's Range | 138.10 - 139.45 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 157.83 (+14.02%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $157.83, which is an increase of 14.02% from the latest price.
News
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $45 and keeps an Overweight rating on the shares. The analyst says Novartis’ (NVS) Phase 3…
Novartis downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis last night downgraded Novartis (NVS) to Hold from Buy with a price target of CHF 120, down from CHF 140. The firm cites pelacarsen and…
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Market Today: Novartis Plunges on Drug Trial Failures; US Market Drops
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
European Markets Steady Amid Novartis Setbacks (NVS)
European Markets Steady Amid Novartis Setbacks (NVS)
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Underweight from Neutral with a price target of $10, down from $17. The firm believes Novartis’ (NVS) Phase 3 trial miss…
Novartis downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis downgraded Novartis (NVS) to Hold from Buy with a CHF 120 price target
Novartis initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Novartis (NVS) with a Sector Perform rating and CHF 120 price target The unexpected pelacarsen failure and del-desiran DM1 setback have “dampened momentum” and highli...
Eli Lilly Stock (LLY) Falls on News of Competitor Novartis’ Cholesterol Drug Setback
Eli Lilly’s ($LLY) stock is down 2% on reports that rival Novartis’ ($NVS) new cholesterol drug failed a closely watched cardiovascular trial.
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
After Sarepta (SRPT) competitor Novartis (NVS) reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to achieve statistical significance on the primary endpoint of…
Swiss Stocks Slide On Novartis Experimental Drug Setback
(RTTNews) - Save for a few minutes at the start, the Switzerland market languished in negative territory on Tuesday, due largely to heavy selling at the drugmaker Novartis counter.
Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone
Mizuho analyst Uy Ear believes Sarepta’s (SRPT) selloff due to Novartis’ (NVS) failed HARBOR Phase 3 study of del-desiran in DM1 is overdone. In the firm’s view, the press release…
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapie...
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss
H.C. Wainwright reiterates a Sell rating on Sarepta (SRPT) with a $5 price target after Novartis (NVS) said its Phase 3 study of del-desiran missed its placebo-controlled primary endpoint. The…
Novartis (NVS) Faces Setbacks in Clinical Trials, Impacting Pipeline and Stock Value
Novartis (NVS) Faces Setbacks in Clinical Trials, Impacting Pipeline and Stock Value
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Novartis's failed trial for cholesterol drug leads to broad biopharma selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase III Trial Disappointment
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase III Trial Disappointment